The document discusses obesity and overweight, defining them as excess body weight and fat storage. It notes that obesity is influenced by both genetic and environmental factors, and identifies some common causes like lack of physical activity, unhealthy diets, pregnancy, lack of sleep, certain medical conditions and medications. The health risks of obesity are also summarized, including increased risk of diseases like diabetes, heart disease, and certain cancers.
Obesity is a chronic heath problem ,the no.of people having obese rising rapidly world wide and making obesity 1 of the fastest developing peoples health problem
Medooc is a search engine for researching medical information.It has been built by medical
professionals to help others in the community to research and share credible health information.
Doctors, Physcials and medical professionals participate in Medooc.com on day to day basis to help each other.
For more information you can visit:-http://www.medooc.com/
Obesity is a chronic heath problem ,the no.of people having obese rising rapidly world wide and making obesity 1 of the fastest developing peoples health problem
Medooc is a search engine for researching medical information.It has been built by medical
professionals to help others in the community to research and share credible health information.
Doctors, Physcials and medical professionals participate in Medooc.com on day to day basis to help each other.
For more information you can visit:-http://www.medooc.com/
My seminar Obesity by Hani
Obesity is a public health and policy problem because of its increase prevalence, costs and health effect. (WHO, 2012, National heart lung and blood institute. 2012)
. The risk factor for chronic disease are highly prevalence (Zindah, Belbeisi, Walke & Makdad 2008)
The obesity and the overweight are risk for number of chronic disease include diabetes cardio vascular disease and cancer (WHO,2010)
This ppt contains all the details about what is obesity, etiology, & mainly focuses on various methods of assessment of obesity from field tests to lab tests.
power point presentation on obesity by Rajeshwaree Netha (Doctor of pharmacy).
contents included are Introduction,pathophyisiology,clinical presentation (signs and symptoms of obesity disorder) ,Treatment,goals of treatment, general approach, Pharmacological treatment, and Evaluation of therapeutic outcomes.
My seminar Obesity by Hani
Obesity is a public health and policy problem because of its increase prevalence, costs and health effect. (WHO, 2012, National heart lung and blood institute. 2012)
. The risk factor for chronic disease are highly prevalence (Zindah, Belbeisi, Walke & Makdad 2008)
The obesity and the overweight are risk for number of chronic disease include diabetes cardio vascular disease and cancer (WHO,2010)
This ppt contains all the details about what is obesity, etiology, & mainly focuses on various methods of assessment of obesity from field tests to lab tests.
power point presentation on obesity by Rajeshwaree Netha (Doctor of pharmacy).
contents included are Introduction,pathophyisiology,clinical presentation (signs and symptoms of obesity disorder) ,Treatment,goals of treatment, general approach, Pharmacological treatment, and Evaluation of therapeutic outcomes.
In today's society, leanness is often equated with beauty, success, fitness, and self-control. Obesity, on the other hand, is considered as undesirable as leanness is desirable, for reasons that are often more related to cosmetic concerns than to actual or potential medical complications.
Preventing diabetes and obesity in mental health disordersHealthXn
Diabetes is common in people with mental health disorders. This presentation discusses why and what therapies may worsen the disorder and how to prevent obesity and diabetes
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
1. Dr. AKHTAR ALI
Resident first year
department of
pharmacology
Dr. S. N. Medical college
Jodhpur (raj.)
2. Obesity represents a state of excess
storage of body fat.
Overweight puristically is defined as an
excess body weight for height.
While adult men have a body fat
percentage of 15-20%, women have a
higher proportion (approximately 25-
30%).
Monday, June 12, 2017
2
3. Now with the (BMI) you
can diagnose yourself as
an obese or not, but still
one problem. Some
people like the muscular
athletes find their (BMI)
higher than normal, when
they most likely have a
normal amounts of fat in
their bodies, and the
answer is that, they
weight more not because
of fat, but because of
muscles.
4. Genetic – familial tendency.
Sex – women more susceptible .
Activity – lack of physical activity.
Psychogenic – emotional deprivation,
depression .
Social class – poorer classes.
Alcohol – problem drinking.
Smoking – cessation smoking.
Prescribed drugs – tricyclic derivatives.
Monday, June 12, 2017
4
6. •Diets: some bad eating habits
like high calories diets epically in
the night, or skipping a healthy
breakfast, and replace it by junk
fast food, all of that increase the
body fat .
•Pregnancy: some women after
the baby is born have an
increasing in their weight, and if
they don’t lose that weight, with
many pregnancies after that,
they may become obese.
7. •Lack of sleep: this cause disturbances
in the body hormones, and increase the
appetite. you also may crave to height
calories food.
•Drugs: some medications lead the
body to gain more weight, these drugs
include, diabetes medications, steroids
and beta blockers, anti-seizure
medications, antipsychotic medications
and antidepressants drugs.
8. •Medical conditions: some diseases and syndromes lead the
body to store more fat and gain weight like Cushing syndrome.
some disease low the metabolic rate in the body and low the
amount of burned calories every day such as the
hypothyroidism. And some diseases lead the patient to low his
activity, such as the arthritis or maybe the patients with
paraplegia
•Genetics: genes affect the amount of body fat we store and
where to store,
•Family lifestyle: not because of the genes we find the obesity
runs in the families, it also because of their life style and the food
they eat. We can notice that some countries such as USA, have
more obese people than others countries like Japan and this is
because the culture and the life style.
9. •Age: obesity could occur at any age, but when we get age
we lose more amount of muscles built. more amount of
muscles give higher rate of metabolism and calories burning.
When we lose them we reduce the calories burning and tend
to fill the body with fat.
Monday, June 12, 2017
9
10. Because differences in weight
among individuals are only
partly due to body fat
variations, body weight is a
rather limited, although easily
obtained, index of obesity.
Monday, June 12, 2017
10
11. Body mass index (BMI), also known as
the Quetelet index, is far more
commonly used to define obesity and
has been found to closely correlate
with the degree of body fat in most
settings.
Monday, June 12, 2017
11
12. BMI = (weight [kg]) / (height [m])2.
Body fat percentage can be estimated
using the Deurenberg equation.
Body fat percentage = 1.2(BMI) +
0.23(age [y]) – 10.8(sex) – 5.4, with
males coded as 1 and females as 0.
This formula has a standard error of
4% and explains approximately 80% of
the variation in body fat.
Monday, June 12, 2017
12
13. Other indices used to estimate the
degree and distribution of obesity
include the 4 standard skin thicknesses
(ie, subscapular, triceps, biceps,
suprailiac) and various anthropometric
measures, of which waist and hip
circumferences are the most important.
Monday, June 12, 2017
13
14. World Health Organization (WHO)
criteria based on BMI. for adults:
grade 1 (overweight ) BMI of 25-
29.9 kg/m2.
Grade 2 overweight (obesity) BMI of
30-39.9 kg/m2.
Grade 3 overweight (severe or
morbid obesity) BMI greater than or
equal to 40 kg/m2.
Monday, June 12, 2017
14
15. Surgical literature ( different
classification) for recognize severe
obesity.
BMI greater than 40 kg/m2 (severe
obesity)
BMI of 40-50 kg/m2 (morbid obesity)
BMI greater than 50 kg/m2 ( super
obese)
Monday, June 12, 2017
15
16. Adipocyte: is the cellular basis for
obesity, is being found to be an
increasingly complex and metabolically
active cell.
the adipocyte is being perceived more
frequently as an endocrine gland with
several peptides and metabolites that
may have relevance to the control of
body weight.
Monday, June 12, 2017
16
17. products of the adipocyte involved in the complex intermediary
metabolism:
cytokines
tumor necrosis factor-alpha
interleukin-6
lipotransin,
adipocyte lipid-binding protein
acyl stimulation protein
prostaglandins
adipsin
perilipins
lactate
adiponectin
monobutyrin
phospholipid transfer protein
Monday, June 12, 2017
17
18. critical enzymes involved in adipocyte
metabolism:
endothelial lipoprotein lipase (involved in lipid
storage)
hormone-sensitive lipase (involved in lipid
elaboration and release from adipocyte depots)
acylcoenzyme A (acyl-CoA) synthetases
(involved in fatty acid synthesis),
and a cascade of enzymes (involved in beta
oxidation and fatty acid metabolism)
Monday, June 12, 2017
18
20. The pathogenesis of obesity is far more
complex than the simple paradigm of
an imbalance between energy intake
and energy output.
Monday, June 12, 2017
20
21. The high prevalence of obesity in the
children of parents who are obese and
the high concordance of obesity in
identical twins suggest a significant
genetic component to the pathogenesis
of obesity, the secular trends of the last
few decades, which are coincident with
recent changes in dietary habits and
activity, also suggest a significant role
for environmental factors.
Monday, June 12, 2017
21
22. Leptin was discovered in 1994 by
Friedman et al and ushered in an
explosion of research and a great
increase in knowledge about regulation
of the human feeding and eating cycle.
Monday, June 12, 2017
22
23. The major role of leptin in body weight
regulation is to signal satiety to the
hypothalamus and, thus, reduce
dietary intake and fat storage while
modulating energy expenditure and
carbohydrate metabolism to prevent
further weight gain.
Monday, June 12, 2017
23
24. Unfortunately, unlike the Ob/Ob mouse
model in which this peptide was first
characterized, most humans who are
obese are not leptin-deficient but
rather leptin-resistant and, thus, have
elevated circulating leptin levels.
Monday, June 12, 2017
24
32. Energy imbalance
calories consumed not equal to
calories used
Over a long period of time
Due to a combination of several
factors
Individual behaviors
Social interactions
Environmental factors
Genetics
Monday, June 12, 2017
32
33. 3500 calories = 1 pound
100 calories extra per day
= 36,500 extra per year
= 10.4 lbs weight gain
Question: How much is 100 calories?
Answer: Not very much!
1 glass skim milk, or
1 banana, or
1 slice cheese, or
1 tablespoon butter
Monday, June 12, 2017
33
34. More in and less out = weight gain
More out and less in = weight loss
Hypothalamus
control center for hunger and satiety
Endocrine disorder
where are the hormones?
Monday, June 12, 2017
34
35. Hormone secreted in the stomach
Acts on the hypothalamus to stimulate
appetite
Levels peak just before meals and drop
afterward
Monday, June 12, 2017
35
36. •Naturally occurring hormone that plays a role in satiety
and weight maintenance.
•Produced in adipocytes
•Its role in weight regulation is related to its effects on the
hypothalamus, where it leads to:
• satiety
•decreased food intake
•increased energy expenditure in the periphery
Monday, June 12, 2017
36
39. Leptin
Dieting decreases leptin levels
Reducing metabolism, stimulating
appetite
Ghrelin
Levels in dieters are higher after weight
loss
The body steps up ghrelin production in
response to weight loss
The higher the weight loss, the higher the
ghrelin levels
Monday, June 12, 2017
39
40. Contributes to approximately 300,000 deaths a year,
making it 2nd
only to smoking as a cause of death
Contributes or causes to many other health problems
including:
Type 2 Diabetes Mellitus
Coronary Artery Disease
Degenerative Joint Disease
Certain Types of Cancer
Nonalcoholic Steatohepatitis
Monday, June 12, 2017
40
43. Major cause of
preventable death
Increase in
mortality from all
causes
Increase in risk for
these cancers
Endometrium
Breast
Prostate
Colon
Increase in risk of:
Hypertension
Dyslipidemia
Diabetes type 2
Coronary artery
disease
Stroke
Gallbladder disease
Osteoarthritis
Sleep apnea &
respiratory
problems
Monday, June 12, 2017
43
44. Assess the patient's readiness and willingness
to lose weight :
Unfortunately those who are most concerned
about their weights are not necessarily those
who are at the highest health risk.
Those who are unable or unwilling to embark
on a weight reduction program, but they are
willing to take steps to avoid further weight
gain or perhaps to work on other risk factors
such as cigarette smoking, and they should
be encouraged to do so.
For those not ready to act, the issue should
be deferred and brought up at the next visit
Monday, June 12, 2017
44
45. Assess for other risk factors
Existing high risk disease:
coronary heart disease; other atherosclerotic
diseases; type 2 diabetes; sleep apnea
Diseases associated with obesity
Gynecological problems; osteoarthritis; gallstones;
stress incontinence
Cardiovascular risk factors (3 or more = high risk)
Cigarette smoking; Hypertension; LDL >130; HDL
<35; fasting glucose = 110 to 125; family history
of premature CHD; men age > 45; women age >
55
Other risk factors
Physical inactivity; elevated serum triglycerides
Medications associated with obesity
Monday, June 12, 2017
45
46. A multi-faceted
approach is best
Diet
Physical activity
Behavior change
“A”
Recommendation
Monday, June 12, 2017
46
47. Initial goal: 10% weight loss
Significantly decreases risk factors
Rate of weight loss
1 to 2 pounds per week
Reduction of caloric intake 500-1000 per day
Slow weight loss is more stable
Rapid weight loss is almost always followed
by weight gain
Rapid weight loss increases risk for
gallstones & electrolyte abnormalities
Monday, June 12, 2017
47
48. Aim for 4 - 6 months of weight loss effort
Most people will lose 20 to 25 pounds
After 6 months, weight loss is more difficult
Ghrelin & Leptin are at work!
Changes in resting metabolic rate
Energy requirements decrease as weight
decreases
Diet adherence wavers
Set goals for weight maintenance for next 6
months, then reassess.
Monday, June 12, 2017
48
49. Weight reduction with dietary treatment
is in order for virtually all patients with a
BMI 25-30 who have comorbidities and
for all patients over BMI 30.
Strategies of dietary therapy include
teaching about calorie content of different
foods, food composition (fats,
carbohydrates, and proteins), reading
nutrition labels, types of foods to buy,
and how to prepare foods.
Monday, June 12, 2017
49
50. 1000 to 1200
kcal/day for women
1200 to 1600
kcal/day for men
Adjust for current
weight & activity
Too hungry?
increase kcal by
100 - 200/day
Not losing?
decrease kcal by
100 - 200/day
Monday, June 12, 2017
50
51. Nutrient Recommended intake
Calories 500 to 1000 kcal/day reduction from
usual
Total fat <30% of total calories
Cholesterol <300 mg per day
Protein <15% of total calories
Carbohydrate >55% of total calories
Sodium
Chloride
<2.4 g sodium, or <6 g sodium chloride
Calcium 1000 to 1500 mg/day
Fiber 20 to 30 g/day
Monday, June 12, 2017
51
52. Physical activity should be an integral part of
weight loss
Physical activity alone is less successful than
a combined diet & exercise program
Increased activity alone
does not decrease weight
Sustained activity does
prevent weight regain
Reduces risk for heart disease & diabetes
Monday, June 12, 2017
52
53. Start slowly
Many obese people live sedentary lives
Avoid injury
Early changes can be activities of daily living
Increase intensity & duration gradually
Long-term goal
30 to 45 minutes or more of physical activity
5 or more days per week
Burn 1000+ calories per week
Monday, June 12, 2017
53
54. What does it take to burn
1000 calories per week?
Running
11 miles
Walking
12 miles
Dancing 3 hours
Gardening
5 hours
Cycling 22 miles
Monday, June 12, 2017
54
55. Keep a journal of diet & activity
Very powerful intervention!
Set specific goals re: behaviors
Eating
Activity
Related behaviors
Track improvement
Weigh & measure on a regular basis
Monday, June 12, 2017
55
56. Focus on the goals
Plan meals & activity
Develop reminder systems
Anticipate temptations & plan resistance
Reward yourself
Limit quantities, but do not deprive
yourself
Have confidence in your ability to
succeed
Do positive self-talk
Monday, June 12, 2017
56
57. •A combined intervention of behavior therapy, dietary
changes and increased physical activity should be
maintained for at least 6 months before considering
pharmacotherapy.
NHLBI Obesity Education Initiative, Expert Panel on the Identification, Evaluation, and Treatment of
Overweight and Obesity in Adults
Monday, June 12, 2017
57
58. BMI of 30 kg/m² or more or a BMI of 27
kg/m² or more with comorbid condition
Understand that drug therapy is adjunctive
to lifestyle intervention
Have realistic expectations about weight
loss goals and outcomes
Demonstrate readiness for change
Are unable to lose/maintain weight with
lifestyle change alone
Comply with medication use
Have no medical or psychiatric
contraindications
Monday, June 12, 2017
58
59. •Weight loss drugs should never be used without continued
concomitant lifestyle modifications and as part of a
comprehensive weight loss program.
•Continual assessment of drug therapy for efficacy and safety is
necessary.
•If the drug is efficacious in helping the patient to lose and/or
maintain weight loss and there are no serious adverse effects, it
can be continued.
•If not, it should be discontinued.
NHLBI Obesity Education Initiative, Expert Panel on the Identification, Evaluation, and Treatment of
Overweight and Obesity in Adults
Monday, June 12, 2017
59
60. Pregnancy or lactation
Unstable cardiac disease
Uncontrolled hypertension (SBP >180, DBP > 110 mmHg)
Unstable severe systemic illness
Unstable psychiatric disorder or history of anorexia
Other drug therapy, if incompatible (eg MAO inhibitors,
migraine drugs, adrenergic agents, arrhythmic potential)
Closed angle glaucoma (caution)
General anesthesia
NHLBI Obesity Education Initiative, Expert Panel on the Identification, Evaluation, and Treatment of
Overweight and Obesity in Adults
Monday, June 12, 2017
60
61. These drugs are only modestly effective
2 to 10 kilogram loss
Most occurs in the first 6 months
If patient does not lose 2 kilograms in
the first 4 weeks, success is unlikely
If the first 6 months is successful,
continue medication as long as…
It is effective in maintaining weight, and
Adverse effects are not serious
Monday, June 12, 2017
61
63. Reducing food intake. Either amplify effects of signals/factors
that inhibit food intake or block signals/factors that augment food intake
Blocking nutrient absorption (especially fat or
carbohydrates) in the intestine.
Increasing thermogenesis. Either increase metabolism and
dissipate food energy as heat or increase energy expenditure through the
enhancement of physical activity.
Modulating fat metabolism/storage. Regulate fat
synthesis/breakdown by making appropriate adjustments to food intake or
energy expenditure.
Modulating the central regulation of body
weight. Either alter the internal set point or modulate the signals
presented regarding fat stores.
Monday, June 12, 2017
63
64. Generic/Brand Name Usual Dose Mechanism of Action Side Effects
•Orlistat/Xenical
•Sibutramine/Meridia
•Phentermine/
Adipex, Fastin,
Ionamin and others
•rimonabant
120 mg with each
meal
5-15 mg/d
15-37.5 mg per
day as a single or
split dose
withdrawal
Peripheral: Blocks
absorption of about
30% of consumed fat
Central: Inhibits
synaptic reuptake of
norepinephrine and
serotonin
Central: Stimulates
release of
norepinephrine
Antagonist og CB1
receptor
GI symptoms (oily
spotting, flatus with
discharge, fecal urgency,
oily stools, incontinence)
Dry mouth,
constipation,
headache, insomnia,
increased blood
pressure, tachycardia
CNS stimulation,
tachycardia, dry
mouth, insomnia,
palpitations
Suicidal tendency
Monday, June 12, 2017
64
65. Generic/Brand Name Usual Dose Mechanism of Action Side Effects
•ephedrine+/-caffeine
"Elsinore"pill
•Bupropion/Wellbutrin
•Topiramate/Topamax
Varies: usually
75-150 mg
ephedrine and
100-150 mg
caffeine
100-300 mg/d
96-192 mg/d
Central: Stimulates
adrenergic receptors
Central: Inhibits
reuptake of
dopamine
norepinephrine and
serotonin
Uncertain: Central ?
CNS stimulation,
tachycardia, dry
mouth, insomnia,
palpitations
CNS stimulation,
dry mouth,
headache, GI
effects
CNS: paresthesia,
fatigue, dizziness,
memory difficulty,
concentration
difficulty, and
depression
Monday, June 12, 2017
65
66. Appetite suppressant that works by blocking
reuptake of serotonin and norepinephrine.
Some experts have postulated that this agent
may be the most effective in helping maintain
weight loss.
Maintaining weight loss has long been the major
downfall to most diet programs.
Until recently, the longest clinical trials with this
agent have lasted 1 year.
Monday, June 12, 2017
66
67. Among obese patients who should undergo drug therapy,
sibutramine works best for those who:
Experience difficulty controlling food intake
Do not feel full
Think about food a lot
Do not have increased cardiovascular disease risk or
multiple risk factors
Are younger
Sibutramine is taken once daily with or without food.
Monday, June 12, 2017
67
68. The use of sibutramine is
contraindicated in patients:
Taking concomitant monoamine
oxidase inhibitor (MAOI) therapy
With anorexia nervosa
Using any other centrally-acting
appetite suppressant
With hypersensitivity to ingredients
of sibutramine
Monday, June 12, 2017
68
69. In addition, sibutramine should not be
used by patients who have:
uncontrolled hypertension
coronary heart disease
congestive heart failure
Arrhythmias
stroke
severe renal or liver dysfunction
Sibutramine should be used with
caution in patients with narrow-angle
glaucoma.
Monday, June 12, 2017
69
70. Can result in dry mouth, constipation,
headache, insomnia, increased blood
pressure, tachycardia.
Should monitor all patients once a
month for hypertension and side effects
Should take in the morning to avoid
insomnia
Monday, June 12, 2017
70
71. Pancreatic lipase inhibitor that blocks the
absorption of up to one third of ingested fat.
In addition to helping reduce weight, orlistat has
been shown to also:
lower plasma low-density lipoprotein cholesterol (LDL)
cholesterol levels.
The decline in LDL cholesterol is greater than that
expected due to weight loss alone.
Lower HgbA1C in diabetic patients
Monday, June 12, 2017
71
72. Among obese patients who meet the criteria for
anti-obesity drug therapy, orlistat is most likely
to benefit those who:
Do not feel hungry
Are not preoccupied with food
Eat out or order-in often
Have increased cardiovascular disease risk or
multiple cardiovascular risk factors
Are older
Take multiple medications
Orlistat is taken 3 times daily with meals
Monday, June 12, 2017
72
73. Because it blocks intestinal absorption of fat it
can result in diarrhea and steatorrhea
This is minimized by maintaining a strict low fat
diet (<30% of diet)
Another concern is the loss of fat soluble vitamins
with a potential for malnutrition.
To prevent this, recommend a daily multivitamin
for all patients on this therapy
Monday, June 12, 2017
73
74. Topiramate is a novel antiepileptic drug approved
by the FDA as an antiseizure medication.
When reports surfaced that patients enrolled in
initial trials of the drug and also in clinical practice
were experiencing unexpected weight loss, the
effects of the drug on weight began to be studied.
Mechanism for weight loss is still poorly
understood
Monday, June 12, 2017
74
76. 47,000 in 2001; 98,000 in 2003
Types of Obesity Surgery:
1. Restrictive Surgery - uses bands or staples to
create food intake restriction:
Vertical Banded Gastroplasty (VBG) - is a “pure”
restrictive surgery since it only involves surgically
creating a stomach pouch. VBG uses bands and
staples and is the most frequently performed
procedure for obesity surgery.
Gastric Banding – involves the use of a band to
create the stomach pouch.
Laparoscopic Gastric Banding (Lap-Band),
approved by the FDA in June 2001, is a less invasive
procedure in which smaller incisions are made to
apply the band. The band is inflatable and can be
adjusted over time
Monday, June 12, 2017
76
77. 2. Combined Restrictive and Malabsorptive
Surgery - is a combination of restrictive surgery
(stomach pouch) with bypass (malabsorptive
surgery), in which the stomach is connected to the
jejunum or ileum of the small intestine, bypassing the
duodenum.
Roux-en-Y Gastric Bypass (RGB) - is the most commonly
performed gastric bypass procedure, and the second most
frequently performed surgery for obesity after VBG. RGB
involves a stomach pouch for food intake restriction. A direct
connection, which is Y-shaped, is made from the ileum or
jejunum to the stomach pouch for malabsorption.
Biliopancreatic Diversion (BPD) - is one of the most
complicated obesity surgery, sometimes involving the
removal of a portion of the stomach. The remaining section
of the stomach is connected to the ileum. BPD successfully
promotes weight loss, but this procedure is typically used for
persons with severe obesity who have a BMI of 50 or more
Monday, June 12, 2017
77
78. Indications
100 pounds overweight or more
Or, BMI > 40
Or, BMI > 35 and 2 significant
comorbidities
Age 18 to 60
Documented failure at nonsurgical
efforts
Psychological stability
Monday, June 12, 2017
78
80. Complications of surgery
Mortality
<1% mortality in healthy young adults BMI < 50
2-4% mortality in patients with disease and BMI >
60
Operative complications
< 10%
Late complications are uncommon
Incisional hernias
Gallstones
Vitamin B12 & iron deficiency
Weight loss failure
Neurologic symptoms in unusual cases
Monday, June 12, 2017
80
81. Durable weight loss
One study followed pts for 14 years
Average excess weight loss =
61.2%
77% with diabetes no longer
require meds
From Wald meta-analysis in JAMA 2004)
Monday, June 12, 2017
81
82. Schedule a return visit in 2 to 4 weeks after
starting weight loss plan
Monitor treatment effectiveness & side
effects
Schedule monthly visits for first 3 months
If making favorable progress
See more frequently if monitoring medical
complications or chronic disease
Reduce frequency of visits after 6 months
Monday, June 12, 2017
82
83. Monitor weight, BP, pulse at each visit
Monitor waist size intermittently
Share progress with patient; praise efforts
Share lab results with patient
Emphasize findings associated with weight
reduction
Focus on medical benefits
Most weight loss doesn’t reach individual’s
‘ideal’ (cosmetic) goal
Monday, June 12, 2017
83